Trial Profile
Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Prognostic Factors of the Age-adjusted IPI
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine; Vindesine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms GAINED
- 14 Dec 2021 Results assessing whether molecular classifier increased the accuracy of lymphoma diagnosis, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 19 Nov 2020 Results published in the Blood.
- 06 Mar 2018 Status changed from active, no longer recruiting to discontinued.